Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in subjects with advanced ovarian cancer: Exploratory analysis of phase III OVA-301 study

Journal article

Peer reviewed

B.J. Monk, P. Ghatage, T. Parekh, E. Henitz, R. Knoblauch, A. Soto Matos-Pita, A. Nieto, Y.C. Park, D. Ricci and A. Poveda

Gynecologic oncology, Vol.133, pp.41-41

06/2014

Metrics

1 Record Views

Title: Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in subjects with advanced ovarian cancer: Exploratory analysis of phase III OVA-301 study
Creators: B.J. Monk - University of Arizona
P. Ghatage - Baker Hughes
T. Parekh - Janssen
E. Henitz - Janssen Research & Development, Raritan, NJ, USA
R. Knoblauch - Janssen
A. Soto Matos-Pita - PharmaMar
A. Nieto - PharmaMar
Y.C. Park - Janssen Research & Development, Raritan, NJ, USA
D. Ricci - Janssen
A. Poveda - Fundación Instituto Valenciano de Oncología
Publication Details: Gynecologic oncology, Vol.133, pp.41-41
Publisher: Elsevier Inc
Identifiers: 991005968774102656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article